How APAC Life Science, R&D and Innovation Real Estate Became a Growth Asset
Conventional commercial properties such as office towers and logistics facilities have long been preferred by institutional investors seeking stable, long-term returns. However, supply chain disruptions stemming from the Covid-19 pandemic as well as ageing demographics have shifted the spotlight towards research labs, manufacturing facilities, and other life science/R&D infrastructure.
Once viewed as a niche, alternative investment, life science and R&D properties are finding their way into mainstream institutional investment portfolios thanks to tailwinds from both government support and long-term healthcare demand. With some of the fastest ageing populations worldwide, the Asia Pacific (APAC) pharmaceutical market size is expected to nearly double from US$497.45 billion in 2026 to US$855.99 billion in 20341. At the same time, regional capital expenditure in energy, defence, and industrials are expected to supercharge from US$11 trillion in 2026 to US$16 trillion by 2030, underscoring the need for innovative facilities with R&D capabilities2.
“APAC is being placed at the centre of life science and innovation for decades to come. The scale of inflowing investments and development plans lead us to believe that we’re witnessing the early stages of a multi-decade story.” - Bart Price, Vita Partners CEO
Rising healthcare and R&D expenditure across APAC
Unlike cyclical industries driven by consumer sentiment, healthcare demand is tied closely to demographic realities that are encouraging governments to invest more proactively into biomedical innovation. China and Japan already operate some of the world’s largest pharmaceutical markets, valued at approximately US$152.79 billion and US$82.67 billion respectively3. Having already introduced higher reimbursement premiums for innovative drug development, Japan has also announced plans to become “the world’s most advanced bioeconomy society” with a bioeconomy market value target of US$837 billion by 20304.
Post-pandemic concerns surrounding supply chain resilience have also accelerated capital deployment into domestic pharmaceutical manufacturing and R&D capabilities. Australia, for example, has introduced initiatives to strengthen sovereign medical manufacturing capabilities following vulnerabilities exposed during the pandemic. The government’s Medical Science Co-investment Plan specifically identifies supply chain diversification and advanced therapeutics manufacturing as strategic priorities for long-term sector growth. Reflecting this broader momentum, public and private medical science R&D spending in the country has grown at an annual rate of approximately 14% over the past five years5.
AI wave pushes demand for innovation real estate
At the same time, the region's focus on innovation-led growth is increasing demand for specialised real estate that supports research, collaboration, and technology development. As governments compete to attract high-value industries and talent, innovation districts and business parks have emerged as critical ecosystems for technology, biomedical, and R&D occupiers. Kampong AI, located in Singapore’s one-north innovation cluster, is expected to attract an additional 70 AI firms as the nation accelerates its AI ambitions6. This trend reflects growing demand for integrated innovation environments that bring together research, talent, and commercialisation capabilities.
Specialised real estate’s advantage over traditional commercial property
Life Science
Life science tenants frequently invest millions of dollars into highly customised fit-outs such as cleanrooms and environmental controls. These technical and regulatory requirements create high barriers to entry that constrain the supply of suitable facilities, while making existing compliant life science assets more defensive from an investment standpoint.
Additionally, relocation is significantly more disruptive and expensive compared to conventional office tenants, leading to what investors often describe as ‘stickier’ tenancy profiles with longer lease commitments. Over time, life science buildings tend to attract research institutions, pharmaceutical manufacturers, healthcare providers, startups, and even universities, creating interconnected ecosystems as demonstrated by Singapore’s Biopolis and Solaris in Fusionopolis.
R&D
Unlike pure life science facilities, R&D spaces often require rapid iteration and cross-disciplinary collaboration. In recent years, configuration flexibility has become increasingly vital as companies face shorter innovation cycles. Demand is not only being driven by traditional research organisations, but also corporations involved in advanced manufacturing, semiconductors, robotics, and deep tech.
The demand for environments that enable continuous experimentation and co-development can be seen in innovation nodes like one-north and the Jurong Innovation District, where research institutions and industry players intentionally co-locate to accelerate commercialisation and knowledge transfer.
Innovation
Innovation real estate environments typically integrate office, laboratory, and light industrial functions within a single district, allowing firms to scale from ideation to deployment without geographic fragmentation. Often facilitated by government planning, these clusters are designed to anchor high-value industries and incubate target growth sectors such as artificial intelligence.
More importantly, these district clusters’ value lies in their support of full innovation cycles, where adjacency to critical research infrastructure and deep talent pools enable rapid development in highly competitive fields.
The case for life science, R&D and innovation real estate allocation
With both high-growth sectors such as artificial intelligence-related infrastructure and data centres, as well as traditional blue-chip industries, facing increasing uncertainty, life science and R&D real estate presents a middle ground of stable income visibility alongside the defensive characteristics of commercial property and long-term APAC healthcare exposure.
Connect with the Vita Partners team to learn more about how life science, R&D and innovation real estate fits within broader long-term investment strategies.
References
- Towards Healthcare - APAC Pharmaceutical Market Insights with Future Projections. 21 April 2026.
- Chetan Anya, Financial Times - Asia is headed towards an industrial supercycle. May 2026.
- Frost & Sullivan - Asia-Pacific Pharmaceutical Industry Outlook 2023. April 2023.
- Cabinet Office, Government of Japan - Bioeconomy Strategy. 3 June 2024.
- Australian Government Department of Industry, Science and Resources - Medical Science Co-investment Plan. 15 April 2024.
- Ashley Lo and Fiona Lam, EdgeProp Singapore - AI driving divergence in office and business park demand in Singapore, India and China: CapitaLand Investment. 23 April 2026.